MAGE-A3 Aptamer Specificity via SELEX and Conjugation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an aptamer capable of recognizing a tumor-associated MAGE-A3 peptide with desirable specificity and affinity, as existing aptamers do not effectively target MAGE-A3 peptides presented by major histocompatibility complex (MHC) molecules on cancer cells.
Innovation Solution
Development of an oligonucleotide aptamer, specifically Ap16 and Ap52, which are designed to target the MAGE-A3 peptide with high affinity, and can be modified with chemical groups such as phosphorothioate caps and conjugated with fluorescent dyes or anti-cancer drugs for enhanced stability and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing aptamers are used to target MAGE-A3 peptides, then the general applicability to various cancer types is achieved, but the binding specificity and affinity are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the aptamer sequence parameters to achieve optimal binding affinity and specificity for MAGE-A3 peptides. The SELEX process iteratively optimizes sequence composition, length, and structural parameters to generate aptamers with enhanced binding characteristics while maintaining broad cancer type applicability through target conservation.
Solution Approach 2:
The patent employs composite materials by combining aptamer sequences with chemical modifications such as phosphorothioate caps and conjugating them with fluorescent dyes or anti-cancer drugs. This creates composite molecules that integrate targeting, detection, and therapeutic functions, thereby improving both binding reliability and therapeutic versatility.
2Reliability
If aptamers are modified with chemical groups and conjugated with drugs, then therapeutic effectiveness is improved, but molecular complexity increases
Solution Approach 1:
The patent merges multiple functions into a single conjugated molecule by combining the MAGE-A3 targeting aptamer with anti-cancer drugs and fluorescent dyes. This creates an integrated theranostic agent that simultaneously provides tumor targeting, therapeutic action, and imaging capability, improving therapeutic effectiveness while managing complexity through functional integration.
Solution Approach 2:
The patent achieves multi-functionality by designing aptamer conjugates that can perform multiple roles: specific tumor cell binding, drug delivery, and fluorescent imaging. The universal aptamer binding domain allows the same conjugate structure to target various MAGE-A3 expressing cancers, while the attached functional moieties provide diverse therapeutic and diagnostic capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers demonstrate specific binding to MAGE-A3 peptides presented by MHC molecules on various cancer cells, including melanomas, leukemia, and other carcinomas, and when conjugated with anti-cancer drugs, they can effectively target and treat tumors by alleviating tumor progression.
Implementation Method 1
Aptamers are oligonucleotides, such as ribonucleic acid (RNA) and single-stranded deoxyribonucleic acid (ssDNA), or peptide molecules that can bind to their targets with high affinity and specificity due to their specific secondary and tertiary structures
Data Source
Figure 1
Figure 2
Figure 3a~3n
AI summary
Disclosed herein is an aptamer targeting a MHC-presented peptide and its uses thereof. The MHC-presented peptide is expressed in various cancer cells; therefor, the aptamer of the disclosure is useful as a bio-tool to label and/or treat peptide-presenting cancer cells. Also disclosed herein is a pharmaceutical composition containing the aptamer.